Company Filing History:
2 out of 24 
1 out of 1 
1 out of 14 Years Active: 2020-2021
Title: **Zhongke Chen: Innovator in Cancer Treatment**
Introduction
Zhongke Chen, an accomplished inventor based in Jiangsu, China, has made substantial contributions to the field of cancer therapeutics. With a focus on innovative solutions for treating diseases related to epidermal growth factor receptor (EGFR) mutations, he holds two patents that highlight his expertise and commitment to advancing medical science.
Latest Patents
Chen's most recent patents concern an EGFR inhibitor free base or acid salt polycrystalline form, along with its preparation method and application. This invention is significant as it specifically addresses an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide. It is designed to inhibit the activity of various EGFR mutants, including L858R, T790M, and exon 19 deletion activating mutants. This polycrystalline form holds promise for preventing and treating cancers, particularly non-small cell lung cancer, and is expected to evolve into a new generation of effective EGFR inhibitors.
Career Highlights
During his professional journey, Zhongke Chen has contributed to prominent pharmaceutical companies, such as Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Biomedical Co., Ltd. His role in these organizations emphasizes the practical application of his innovative research and inventions in the pharmaceutical industry.
Collaborations
Chen has worked alongside notable colleagues, including Fuping Liu and Lei Liu. These collaborations have further enriched his research and development efforts, leading to advancements in cancer treatment.
Conclusion
Zhongke Chen is a distinguished inventor whose work is paving the way for more effective cancer treatments. With his innovative patents addressing critical issues in EGFR mutation-related diseases, he is a vital contributor to the ongoing fight against cancer. His dedication to research, combined with his collaborations in the pharmaceutical sector, continues to inspire advancements in healthcare.